National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2011 (No. 7) (No. PB 53 of 2011)

Link to law: https://www.comlaw.gov.au/Details/F2011L01543

 
PB 53 of 2011
National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2011 (No. 7)
 
National Health Act 1953
___________________________________________________________________________
 
 
I, FELICITY MCNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Amendment Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.
Dated  22  July 2011
 
 
 
 
 
 
 
 
 
 
 
FELICITY MCNEILL
Acting First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
 
___________________________________________________________________________
 
 
 
 
1              Name of Instrument
 
(1)                This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2011 (No.7).
 
(2)                This Instrument may also be cited as PB 53 of 2011.
 
2             Commencement
                             This Instrument commences on 1 August 2011.
3              Amendments to PB 116 of 2010
                Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).
.
 
 
Schedule 1                   Amendments
 
[1]       Schedule 1, after entry for Epoetin Alfa in the form Injection 20,000 units in 0.5 mL pre-filled syringe
 
omit:
 
Injection 30,000 units in 0.75 mL pre‑filled syringe
Injection
Eprex 30,000
JC
EMP
C1957 C3334
 
12
5
D
 
 
[2]         Schedule 1, entry for Etanercept
 
omit from the column headed Responsible Person (all instances):
                    WX
 
             and substitute (all instances):
                    PF
 
[3]           Schedule 1, entry for Filgrastim
substitute:
 Filgrastim
Injection 120 micrograms in 0.2 mL single use pre-filled  syringe
Injection
Nivestim
HH
EMP
C2912 C2913
C2914 C2915
C2916 C2917
C2918 C2919
C2920 C2921
C2922 C2923
C2924 C2925
C2926 C2927
C2928 C2929
C2930 C3087
 
20
11
D
 

 
 
 
 
 
 
C3187 C3357
C3358 C3359
C3360 C3361
C3362 C3363
C3364 C3365
C3366 C3367
C3368 C3369
C3370 C3371
C3372 C3373
C3374 C3375
C3376 C3377
 
 
 
 

 
Injection 300 micrograms in 1 mL
Injection
Neupogen
AN
EMP
C2912 C2913
C2914 C2915
C2916 C2917
C2918 C2919
C2920 C2921
C2922 C2923
C2924 C2925
C2926 C2927
C2928 C2929
C2930 C3087
C3187 C3357
C3358 C3359
C3360 C3361
C3362 C3363
C3364 C3365
C3366 C3367
C3368 C3369
C3370 C3371
C3372 C3373
C3374 C3375
C3376 C3377
 
20
11
D

 
 
 
 
 

 
Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Neupogen)
Injection
Neupogen
AN
EMP
C2912 C2913
C2914 C2915
C2916 C2917
C2918 C2919
C2920 C2921
C2922 C2923
C2924 C2925
C2926 C2927
C2928 C2929
C2930 C3087
C3187 C3357
C3358 C3359
C3360 C3361
C3362 C3363
C3364 C3365
C3366 C3367
C3368 C3369
C3370 C3371
C3372 C3373
C3374 C3375
C3376 C3377
 
20
11
D

 
Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Nivestim)
Injection
Nivestim
HH
EMP
C2912 C2913
C2914 C2915
C2916 C2917
C2918 C2919
C2920 C2921
C2922 C2923
C2924 C2925
C2926 C2927
C2928 C2929
C2930 C3087
C3187 C3357
C3358 C3359
C3360 C3361
C3362 C3363
C3364 C3365
C3366 C3367
C3368 C3369
C3370 C3371
C3372 C3373
C3374 C3375
C3376 C3377
 
20
11
D

 
Injection 480 micrograms in 1.6 mL
Injection
Neupogen
AN
EMP
C2912 C2913
C2914 C2915
C2916 C2917
C2918 C2919
C2920 C2921
C2922 C2923
C2924 C2925
C2926 C2927
C2928 C2929
C2930 C3087
C3187 C3357
C3358 C3359
C3360 C3361
C3362 C3363
C3364 C3365
C3366 C3367
C3368 C3369
C3370 C3371
C3372 C3373
C3374 C3375
C3376 C3377
 
20
11
D

 
Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Neupogen)
Injection
Neupogen
AN
EMP
C2912 C2913
C2914 C2915
C2916 C2917
C2918 C2919
C2920 C2921
C2922 C2923
C2924 C2925
C2926 C2927
C2928 C2929
C2930 C3087
C3187 C3357
C3358 C3359
C3360 C3361
C3362 C3363
C3364 C3365
C3366 C3367
C3368 C3369
C3370 C3371
C3372 C3373
C3374 C3375
C3376 C3377
 
20
11
D

 
Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Nivestim)
Injection
Nivestim
HH
EMP
C2912 C2913
C2914 C2915
C2916 C2917
C2918 C2919
C2920 C2921
C2922 C2923
C2924 C2925
C2926 C2927
C2928 C2929
C2930 C3087
C3187 C3357
C3358 C3359
C3360 C3361
C3362 C3363
C3364 C3365
C3366 C3367
C3368 C3369
C3370 C3371
C3372 C3373
C3374 C3375
C3376 C3377
 
20
11
D

 
 
 
 
 
 
 
[4]            Schedule 1, entry for Infliximab
 
    omit from the column headed Responsible Person:
                    SH
 
                and substitute:
                    JC
 
[5]            Schedule 1, entry for Maraviroc
 
    omit from the column headed Responsible Person (all instances):
                    PF
 
               and substitute (all instances):
                    VI
 
[6]            Schedule 1, entry for Sirolimus
 
    substitute:
 
Sirolimus
Tablet 0.5 mg
Oral
Rapamune
PF
EMP
C1650 C3355
 
200
5
C

 
Tablet 1 mg
Oral
Rapamune
PF
EMP
C1650 C3355
 
200
5
C

 
Tablet 2 mg
Oral
Rapamune
PF
EMP
C1650 C3355
 
200
5
C

 
Oral solution 1 mg per mL, 60 mL
Oral
Rapamune
PF
EMP
C1650 C3355
 
200
5
C

 
 
 
 
[7]          Schedule 2:
                   
                after:
SC
Bayer Australia Ltd
22 000 138 714
 
      omit:
SH
Schering-Plough Pty Limited
57 000 235 245
 
 
[8]          Schedule 2:
                after:
VI
ViiV Healthcare Pty Ltd
46 138 687 448
 
                   omit:
WX
Wyeth Australia Pty Limited
16 000 296 211
 
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 
See http://www.frli.gov.au.
 
Read Entire Law on www.comlaw.gov.au